Cytosorbents Reports Q1 2026 Results; DrugSorb-ATR FDA Submission Delayed to Late 2026/Early 2027

summarizeSummary

Cytosorbents reported a widened net loss for Q1 2026 and continued cash burn, while also announcing a delay in the FDA submission for its key DrugSorb-ATR product to late 2026 or early 2027.

check_boxKey Events

• Q1 2026 Financial Results

  Net loss widened to $5.1 million ($0.08/share) from $1.5 million ($0.02/share) year-over-year, primarily due to non-cash foreign currency impacts. Revenue increased 2% to $8.9 million, and adjusted net loss improved to $3.4 million.

• Continued Cash Burn

  Cash and equivalents decreased by $1.4 million to $6.4 million, with a cash burn of $1.1 million in the quarter, further impacting liquidity following previous going concern warnings.

• DrugSorb-ATR Regulatory Delay

  The FDA submission for DrugSorb-ATR (for Brilinta) is delayed to late 2026 or early 2027, as the FDA requested additional mechanistic data, pushing back a critical approval timeline.

• New DOAC Regulatory Path

  The company plans to submit a pre-submission request to the FDA within 30 days for a parallel De Novo application for DrugSorb-ATR to remove DOACs (Eliquis®, Xarelto®), representing a potential new market opportunity.

auto_awesomeAnalysis

This 8-K reports Q1 2026 financial results, showing a significant increase in net loss to $5.1 million, primarily due to non-cash foreign currency impacts, despite improvements in adjusted net loss and operating loss. The company also reported a cash burn of $1.1 million for the quarter, reducing its cash position to $6.4 million. Critically, the FDA submission for DrugSorb-ATR (for Brilinta) is now delayed to late 2026 or early 2027, requiring additional mechanistic data, which is a setback for a key product. This comes amidst prior warnings about liquidity and Nasdaq compliance issues, making the continued cash burn and regulatory delay particularly concerning for the company's near-term outlook.